With respect to the latter, many preclinical reports that show promise in terms of regulating ABC transporters to overcome chemotherapeutic drug resistance in tumours, or modify lipid homeostasis in order to reduce atherosclerotic risk, have not achieved the same level of success in clinical trials. Here, ABCG2 is linked to neoplasm.